Illumina (NASDAQ:ILMN) has been assigned a $275.00 price target by research analysts at Deutsche Bank in a note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the life sciences company’s stock. Deutsche Bank’s price target suggests a potential upside of 11.37% from the stock’s previous close.
Several other research firms have also weighed in on ILMN. Citigroup raised their price objective on shares of Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, October 25th. Robert W. Baird upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $184.00 to $228.00 in a research report on Wednesday, October 25th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. Barclays raised their price objective on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 25th. Finally, BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $220.13.
Illumina (ILMN) traded up $2.20 during trading on Tuesday, reaching $246.92. 101,043 shares of the company’s stock traded hands, compared to its average volume of 1,170,022. The firm has a market cap of $36,090.00, a PE ratio of 46.59, a price-to-earnings-growth ratio of 3.30 and a beta of 0.79. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. Illumina has a 52-week low of $156.50 and a 52-week high of $245.96.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the company earned $0.97 EPS. equities research analysts anticipate that Illumina will post 3.76 earnings per share for the current year.
In other news, Director Robert S. Epstein sold 1,250 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $226.55, for a total value of $283,187.50. Following the completion of the sale, the director now directly owns 9,088 shares of the company’s stock, valued at $2,058,886.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Omead Ostadan sold 3,540 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.91, for a total transaction of $803,261.40. Following the completion of the sale, the executive vice president now directly owns 26,827 shares of the company’s stock, valued at $6,087,314.57. The disclosure for this sale can be found here. Insiders sold 137,671 shares of company stock valued at $29,485,768 over the last three months. 0.89% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of ILMN. Advisory Services Network LLC raised its position in Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares in the last quarter. Dupont Capital Management Corp bought a new position in Illumina during the third quarter valued at approximately $153,000. Patten Group Inc. raised its position in Illumina by 71.1% during the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after acquiring an additional 615 shares in the last quarter. West Coast Financial LLC bought a new position in Illumina during the third quarter valued at approximately $216,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in Illumina during the second quarter valued at approximately $226,000. 91.60% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Deutsche Bank Reiterates $275.00 Price Target for Illumina (ILMN)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/16/deutsche-bank-reiterates-275-00-price-target-for-illumina-ilmn.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.